A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of the Monoclonal Antibody VYD222 in Healthy Adult Participants

NCT05791318 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19

Interventions

DRUG: VYD222
OTHER: Placebo

Sponsor

Invivyd, Inc.

Collaborators

[object Object]